Please assess the completion status of the following clinical trial:

Trial Title: T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with the diagnosis of:~  * De novo acute myeloid leukaemia in first or second remission.~ * Secondary acute myeloid leukaemia in first or second remission supervening after myelodysplastic syndrome or cytotoxic / immunosuppressive therapy.~ * Acute lymphoblastic leukaemia in first or second remission.~ * Myelodysplastic syndrome.~ * Chronic myeloid leukaemia, patients who are candidate for SCT.~ * Malignant lymphoma following relapse or first line therapy resistant.~ * Aggressive mantle cell lymphoma in first complete remission.~* Age 18-65 years.~* WHO performance 0-1 (see appendix ).~* Availability of an HLA-identical sibling or HLA, A, B, DRB, DQB -identical VUD donor.~* Life expectancy \> 3 months.~* Witnessed written informed consent.~Exclusion Criteria:~* Patients with severe cardiac dysfunction (NYHA-classification II-IV)~* Patients with severe pulmonary dysfunction (vital capacity or diffusion \< 70% of predicted value).~* Patients with hepatic dysfunction, bilirubin or transaminases \> 2.5 x upper normal limit~* Patients with renal dysfunction, serum creatinin \> 150 umol/liter or clearance \< 40 ml/minute.~* Patients with a history of moderate ore severe CNS disturbances and psychiatric problems.~* Prior treatment with chemotherapy, immunotherapy, radiation therapy or surgery within the last 3 weeks before entering the study.~* Patients with active uncontrolled infections.~* Patients who are poor medical risks because of non malignant systemic disease.~* Patients with severe coagulopathy.~* Patients to be known HIV positive.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).